Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Mesoblast Limited ( (AU:MSB) ) has issued an announcement.
Mesoblast Limited has announced the issuance of 97,680,000 fully paid ordinary shares to institutional and sophisticated investors through a private placement. This move is part of their strategic financing efforts to support ongoing and future growth initiatives. The issuance was conducted without disclosure under Part 6D.2 of the Corporations Act, and Mesoblast has confirmed compliance with the relevant legal provisions, indicating no awareness of any excluded information that might affect investor interests.
More about Mesoblast Limited
Mesoblast Limited operates in the biotechnology industry, focusing on the development of regenerative medicine products. The company specializes in cellular medicines to treat inflammatory diseases, cardiovascular diseases, and orthopedic conditions, positioning itself in the advanced therapeutics market.
YTD Price Performance: 5.45%
Average Trading Volume: 123,813
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $1.97B
Find detailed analytics on MSB stock on TipRanks’ Stock Analysis page.
